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It is remarkable that Dr Scott begins his response[1] to our rebuttal[2] of 
his earlier editorial[3] by stating that his paper ‘tries to avoid covering 
all the arguments put forward’ by us. Indeed, our impression is that he 
has merely repeated the position in the earlier editorial, that he uses 
rhetorical devices to distort our views, and that he ignores the key points 
we have made.
First, Dr Scott repeats his statement that our position statement 
suffers from confirmatory bias, and fails to address the evidence base 
on harms and benefits of drugs that we cite. He distorts our views by 
drawing an analogy between our citations of this evidence base and past 
misconceptions about antiretrovirals. We think that other clinicians will 
agree that the point made in our rebuttal – that substances are associated 
with well-researched harms, as well as with potential benefits – cannot 
simply be ignored.
Second, Dr Scott again laments the various United Nations (UN) 
conventions, and the harms associated with current drug laws. He 
distorts our views by accusing us of supporting the UN conventions and 
failing to recognise harms associated with current drug laws. However, 
as we stated in our rebuttal, the intention of our position statements is 
precisely to bring attention to and advocate for harm reduction, both 
with respect to cannabis and more generally, as a key public health 
approach to addressing tobacco, alcohol and other substance use. 
Third, Dr Scott again draws a stark contrast between prohibition 
and legal regulation, criticising decriminalisation as merely a form 
of prohibition. He distorts our views by assuming that we stand 
wholly for prohibition. In our rebuttal we emphasised that a broad 
range of regulatory options lie between decriminalisation and 
commercialisation, noting that decriminalisation is merely one 
practical step in the right direction. The evidence indicates that ‘Big 
Cannabis’ is not an imaginary construct that can simply be ignored.
Nevertheless, we would note, as we did in our earlier rebuttal, 
some overlap between our position and Dr Scott’s. We seem to agree 
on a public health approach to the regulation of tobacco, alcohol and 
other substances, on a focus on harm reduction rather than a ‘war on 
drugs’, and on the recognition that alcohol is the most widely used 
and harmful substance in the South African context and so deserving 
of particularly careful regulation. We hope that many clinicians, as 
well as members of the public, will also find common ground on 
these issues.
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